As of April 16, 2025, Emergent BioSolutions (EBS) has a market cap of $0.25 billion USD. According to our data, Emergent BioSolutions is ranked No.6732 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 16, 2025 | $0.25 B |
-51.43%
|
Dec 31, 2024 | $0.52 B |
298.33%
|
Dec 29, 2023 | $0.13 B |
-79.68%
|
Dec 30, 2022 | $0.64 B |
-72.83%
|
Dec 31, 2021 | $2.36 B |
-51.48%
|
Dec 31, 2020 | $4.85 B |
66.08%
|
Dec 31, 2019 | $2.92 B |
-8.99%
|
Dec 31, 2018 | $3.21 B |
27.57%
|
Dec 29, 2017 | $2.52 B |
41.50%
|
Dec 30, 2016 | $1.78 B |
-17.92%
|
Dec 31, 2015 | $2.17 B |
46.93%
|
Dec 31, 2014 | $1.48 B |
18.44%
|
Dec 31, 2013 | $1.25 B |
43.33%
|
Dec 31, 2012 | $0.87 B |
-4.75%
|
Dec 30, 2011 | $0.91 B |
-28.22%
|
Dec 31, 2010 | $1.27 B |
72.63%
|
Dec 31, 2009 | $0.74 B |
-47.95%
|
Dec 31, 2008 | $1.41 B |
416.01%
|
Dec 31, 2007 | $0.27 B |
-54.66%
|
Dec 29, 2006 | $0.60 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Pfizer
PFE
|
$127.27 B |
-0.003 M
|
![]() USA
|
![]() Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
![]() USA
|
![]() Moderna
MRNA
|
$10.14 B |
-0.001 M
|
![]() USA
|
![]() AstraZeneca
AZN
|
$210.42 B |
-0.005 M
|
![]() UK
|
![]() GlaxoSmithKline
GSK
|
$72.33 B |
-0.002 M
|
![]() UK
|
![]() Sanofi
SNY
|
$123.58 B |
-0.002 M
|
![]() France
|
![]() Merck
MRK
|
$197.26 B |
0.003 M
|
![]() USA
|
![]() Novavax
NVAX
|
$1.03 B |
0.000 M
|
![]() USA
|
![]() BioNTech
BNTX
|
$23.80 B |
0.001 M
|
![]() Germany
|
![]() Regeneron Pharmaceuticals
REGN
|
$60.99 B |
1.014 B
|
![]() USA
|
![]() Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
![]() USA
|
![]() AbbVie
ABBV
|
$312.76 B |
-0.013 M
|
![]() USA
|
![]() Amgen
AMGN
|
$158.77 B |
0.132 B
|
![]() USA
|
![]() Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
![]() USA
|
Market Cap | = | EBS Stock Price | * | EBS Shares Outstanding |
= | $4.63 | * | 54.34 M | |
= | $0.25 B |